How Big Is the Cephalosporin Market | Industry Trends & Forecast 2025

Code: MTA4775 Publication Date: Jul 2025

How big is the Cephalosporin Market?

According to 6Wresearch internal database and industry insights, the Global Cephalosporin Market was valued at approximately USD 15.2 billion in 2024 and is projected to reach USD 22.8 billion by 2031, growing at a CAGR of 5.9% during the forecast period.

This growth is driven by the rising global burden of bacterial infections, increasing antibiotic resistance, and demand for broad-spectrum antibiotics across healthcare settings.

Key Growth Drivers of the Cephalosporin Market

  • High prevalence of respiratory, urinary tract, and skin infections
  • Increased use of cephalosporins in both hospital and outpatient care
  • Demand for effective alternatives amid rising antibiotic resistance
  • Expanding elderly population and immunocompromised patient base
  • Continued R&D into combination therapies and novel cephalosporin classes

Cephalosporin Market Trends

The cephalosporin market is witnessing growing interest in combination drugs that include beta-lactamase inhibitors to counter resistance. Injectable cephalosporins are seeing higher demand in acute care settings, while oral formulations remain dominant in outpatient treatments. There is also a surge in demand for third- and fourth-generation cephalosporins due to their effectiveness against multidrug-resistant strains. Additionally, several countries are witnessing a shift toward generic formulations to reduce treatment costs and improve accessibility.

Emerging Developments in the Cephalosporin Market

Other advancements are in making cephalosporin-antiviral combination in treating co-infections. There are advanced delivery options that are being studied including the use of nanoparticle carriers, and extended-release injectables. The international health agencies are pressuring prescriptions of antibiotics by the implementation of antibiotic stewardship programs, which may shape prescription practices. Pharma companies and governments are forming more partnerships to further increase access to critical antibiotics in low- and middle-income nations. Interest is also growing in production of cephalosporins using plants and using fermentation to promote sustainability.

Major Companies in the Cephalosporin Market

  • GlaxoSmithKline
  • Pfizer Inc.
  • Aurobindo Pharma
  • Lupin Pharmaceuticals
  • Sandoz (Novartis)
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries Ltd.
  • Shionogi & Co., Ltd.
  • Orchid Pharma
  • Alkem Laboratories
How Big Is the Cephalosporin Market : FAQ's
The market was valued at USD 15.2 billion in 2024 and is projected to reach USD 22.8 billion by 2031 at a CAGR of 5.9%.
Third- and fourth-generation cephalosporins, especially in injectables.
Rising infection rates, expanding geriatric population, and broad-spectrum effectiveness.
Antibiotic resistance, strict regulatory controls, and pricing pressures on generics.
6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com
6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Industry Events and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Whitepaper

Read All